Acotec : A Leading Global Innovative Medical Technology Enterprise

A Leading Global Innovative Medical Technology Enterprise focusing on the R&D and application of technology platforms in vascular interventional treatment. Relying on four unique technology platforms of drug-coating technology, RF ablation technology, polymer material technology, and aspiration platform technology, Acotec stays the course of reliable innovative ideas to continuously exploit unmet clinical needs, which provides brand-new treatment methods and reliable products for both doctors and patients.


With its diversified product portfolio, Acotec will continuously sustain innovation in vascular intervention treatment to struggle against vascular diseases. On the way of becoming one of the global leaders among medical technology enterprises, Acotect helps patients achieve long-term clinical benefits and improve their life quality by constantly bringing high-quality systemic vascular interventional treatment solutions to doctors and patients worldwide.




Our Value

Our Values

Promote human health

Bring new treatment methods and reliable products to doctors and patients and improve the holistic level of vascular disease treatment so that more patients with vascular diseases can return to a healthy life with high-quality

Our Values

Make constant innovation

Make constant innovation: Adhere to reliable innovative ideas with our imaginative mind to continuously provide new treatment methods and reliable products and open up the next frontier of vascular interventional treatment

Our Values

Respect clinical facts and evidences

Aim at long-term clinical benefits, respect facts and evidence, and explore unmet clinical needs to offer more possible solutions for treating vascular diseases

2022年

Radiofrequency ablation(RFA) system obtains approval for marketing.

· The complete set of RF ablation equipment was approved for market

· The expansion of DCB used for AVF of hemodialysis patients was approved by NMPA

· The percutaneous support catheter (Vericor) was approved by NMPA for market

· The intracranial balloon dilatation catheter (NEO-Skater) was approved by NMPA for market

· The PTA catheter (P-Conic) was approved by NMPA for market

· The coronary artery balloon dilatation catheter (YAN) was approved by NMPA for market

· Our products have been commercialized in 13 countries across the world

2021年

Acotec goes public in HKEX.

· The company was listed in HKEX

· The complete set of equipment of percutaneous vascular aspiration system was approved by NMPA for market

2020年

AcoArt Tulip™ & Litos™(膝下DCB)获批上市

· AcoArt Tulip® & Litos® (the world's first clinically proven below-the-knee DCB) was approved by NMPA for market

· The company acquired Shenzhen Vascupatent to establish the Shenzhen Polymer Material R&D Center


2019年

AcoArt Tulip™ & Litos™(膝下DCB)被FDA评定为“突破性医疗器械

· AcoArt Tulip® & Litos® (below-the-knee DCB) were granted the "Breakthrough Device Designation" by FDA


2016年

AcoArt Orchid & Dhalia(膝上DCB)获批上市

· AcoArt Orchid® & Dhalia® (above-the-knee DCB) were approved by NMPA for market

2014年

PTA获批上市

· PTA was approved by NMPA for market

· The products of DCB and PTA was passed the CE certification and launched in Europe

· The company was nominated as the "Core Enterprise" of the Beijing Economic-technological Development Area

2012年

DCB在十二五期间被列入国家科技支撑计划

· DCB was included in the National Key Technology Research and Development Program during the 12th Five-Year Plan


2011年

Acotec was foundedAcotec was founded

· Beijing Acotec  was founded

· Initiate R&D of the percutaneous transluminal angioplasty (PTA) catheter and the drug-coated balloon (DCB)


2022年

Radiofrequency ablation(RFA) system obtains approval for marketing.

· The complete set of RF ablation equipment was approved for market

· The expansion of DCB used for AVF of hemodialysis patients was approved by NMPA

· The percutaneous support catheter (Vericor) was approved by NMPA for market

· The intracranial balloon dilatation catheter (NEO-Skater) was approved by NMPA for market

· The PTA catheter (P-Conic) was approved by NMPA for market

· The coronary artery balloon dilatation catheter (YAN) was approved by NMPA for market

· Our products have been commercialized in 13 countries across the world

2021年

Acotec goes public in HKEX.

· The company was listed in HKEX

· The complete set of equipment of percutaneous vascular aspiration system was approved by NMPA for market

2020年

AcoArt Tulip™ & Litos™(膝下DCB)获批上市

· AcoArt Tulip® & Litos® (the world's first clinically proven below-the-knee DCB) was approved by NMPA for market

· The company acquired Shenzhen Vascupatent to establish the Shenzhen Polymer Material R&D Center


2019年

AcoArt Tulip™ & Litos™(膝下DCB)被FDA评定为“突破性医疗器械

· AcoArt Tulip® & Litos® (below-the-knee DCB) were granted the "Breakthrough Device Designation" by FDA


2016年

AcoArt Orchid & Dhalia(膝上DCB)获批上市

· AcoArt Orchid® & Dhalia® (above-the-knee DCB) were approved by NMPA for market

2014年

PTA获批上市

· PTA was approved by NMPA for market

· The products of DCB and PTA was passed the CE certification and launched in Europe

· The company was nominated as the "Core Enterprise" of the Beijing Economic-technological Development Area

2012年

DCB在十二五期间被列入国家科技支撑计划

· DCB was included in the National Key Technology Research and Development Program during the 12th Five-Year Plan


2011年

Acotec was foundedAcotec was founded

· Beijing Acotec  was founded

· Initiate R&D of the percutaneous transluminal angioplasty (PTA) catheter and the drug-coated balloon (DCB)


We have several branch offices all around the world

Shanghai, China

Shanghai Office

Room 603, T1, IMShanghai, Line 1388, Kaixuan Road, Changning District, Shanghai

Beijing, China

Beijing Headquarters 

4-5/F., Building 1, No. 16, North Hongda Road, Beijing Economic-technological Development Area, Beijing, PRC

Tel:010-67872107

Fax:010-67866678

Guangzhou, China

Room 2705, R&F Goodrich Building, No. 3, Huaqiang Road, Tianhe District, Guangzhou City, Guangdong Province


California, United States of America

Shenzhen, China

Room 314 & Room 316, Building A, Life Science Park Branch 3, No. 22, East Jinxiu Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen

Tel:0755-89663013


Way of Compliance Reporting:compliance@acotec.cn